Ipsen

  • Français
Symbol Last Change
IPN.PA 36.18 € (-1.79%)
powered by Euronext©
  • The Group
    • Profile & Key figures
      • Message from the Chairman
      • Group history
    • Strategy
    • R & D
      • R & D Homepage
      • Oncology
      • Endocrinology
      • Neurology
      • Primary care
    • Medicines
    • Governance
      • Board of directors
      • Executive committee
      • Board committees
    • Business Development & Alliance Management
    • Ipsen worldwide
  • Targeted diseases
    • Oncology
    • Endocrinology
    • Neurology
    • Hematology
    • Primary care
  • Commitments
    • Vision, mission and values
    • Environment, health and safety
    • Ethics and compliance
    • Support to Patient Organizations
    • Solidarity
  • Fondation IPSEN
    • La Fondation Ipsen at a glance
    • Colloques, prizes, publications
      • Neurosciences
      • Alzheimer’s disease
      • Endocrinology
      • Cancer science
      • Longevity
      • Vascular
    • Partnerships
      • Salk Institute - Nature
      • Cell Press - Massachusetts General Hospital
      • Nature Publishing Group

Press releases

  • 5 March 2010 - Paris (France)
    Launch by Menarini and Ipsen of ADENURIC® (febuxostat) in France for the treatment of chronic hyperuricemia in gout
    application/pdf icon
    Download
  • 1 March 2010 - Paris (France)
    Ipsen's 2009 results and objectives
    application/pdf icon
    Download the press release
    application/pdf icon
    Download the presentation
  • 19 February 2010 - Paris (France)
    “Epigenetic Dynamics in the Immune System”
    application/pdf icon
    Download

All press releases

News

23 February 2010
Monday 1st March 2010 : Publication of Ipsen’s full year 2009 results
Lire la suite

All news

  • Go to

    PrintPrint
    • Press room
    • Investor relations
    • Careers

    YOUR SERVICES

    • Email alert
    • Recommend this website
© Ipsen 2010
  • Legal disclaimer
  • Site Map
  • Contact
  • Email alert
  • RSS
  • Ipsen worldwide
  • IPSEN related sites

Ipsen Group website.